Skip to main content
. 2021 Mar 4;9:635122. doi: 10.3389/fcell.2021.635122

TABLE 4.

Regulation of CHM on TIMPs in TME of murine tumor models.

TCM herbs and their components Murine cancer xenograft models TIMPs Mechanisms References
PGDN B16F10 cells induced melanoma TAMs To skew TAMs polarity toward the M1 phenotype Cao Y. et al. (2019)
GLT AOM/DSS-induced colorectal cancer model TAMs To reduce TAM production Sui et al. (2020)
RSV LLC lung cancer model TAMs To diminish tumor-associated M2 polarized macrophages Sun et al. (2017)
DNC 4T1 breast cancer model. TAMs To diminish tumor-associated M2 polarized macrophages Shiri et al. (2015)
QRHX LLC lung cancer model TAMs To decrease TAM production Xu et al. (2017)
YPF LLC-Luc-induced lung cancer model TAMs To promote the transformation of M2 phenotype to M1 phenotype Wang Y. et al. (2019)
TR 4T1 breast cancer model/AOM/DSS-induced colorectal cancer model TAMs To skew TAMs polarity toward the M1 phenotype Li et al. (2020)
CT JC-induced breast cancer model DCs To activate DCs to present antigens to T cell Chang et al. (2011)
PPS TC-1 cervical cancer model TADCs To reverse the immature state of TADCs Wang Y. et al. (2019)
PAMB PCPP 4T1 breast cancer model DCs To improve DC immune activity Chang et al. (2015)
SBS AOM/DSS-induced colorectal cancer model MDSCs To block the immunosuppressive activity of MDSCs Lin et al. (2015)
SGJP 4T1 breast cancer model MDSCs To block the immunosuppressive activity of MDSCs Lu et al. (2017)
PA 4T1 breast cancer model MDSCs To decrease the number of MDSCs Zheng et al. (2018)
RSV LLC lung cancer model MDSCs To inhibit the function of MDSCs Zhao Y. et al. (2018)
AP, AS, CS, SD 4T1 breast cancer model MDSCs To diminish the number of Tregs and MDSCs Yue et al. (2018)
KRG EL-4 thymoma model MDSCs To disrupt the function of MDSCs Jeon et al. (2011)
JHD H22 hepatoma carcinoma model MDSCs To inhibit immunosuppressive activity of MDSCs Xie et al. (2020)
ART 4T1 breast cancer model MDSCs To impair the activity of Tregs and MDSCs Cao Y. et al. (2019)
YHD 4T1 breast cancer model MDSCs To inhibit the activity of MDSCs Mao et al. (2018)
ICA 4T1 breast cancer model MDSCs To impair the suppressive activity of MDSCs Zhou et al. (2011)
CA LM85 osteosarcoma model. MDSCs To block the function of MDSCs Horlad et al. (2013)
BYJD 4T1 breast cancer model MDSCs To decrease the number of MDSC Tian et al. (2020)

AP, Andrographis paniculata (Burm.f.) Nees; AS, Eleutherococcus senticosus (Rupr. & Maxim.) Maxim.; CS, Camellia sinensis (L.) Kuntze; SD, Scleromitrion diffusum (Willd.) R.J. Wang; ART, artemisinin; BYJD, Bao-Yuan-Jie-Du decoction; CA, corosolic acid; CT, Carthamus tinctorius L.; DC, dendritic cells; DNC, dendrosomal curcumin; GLT, Garcinia livingstonei T. Anderson; ICA, icariin from Epimedium sagittatum (Siebold & Zucc.) Maxim.; JHD, Jianpi Huayu decoction; KRG, Korean red ginseng; MDSCs, myeloid-derived suppressor cells; PA, water extract of pilose antler; PAMB or PCPP, polysaccharide purified from Astragalus mongholicus Bunge or Codonopsis pilosula subsp. pilosula; PGDN, Panax ginseng C. A. Mey.-derived nanoparticles; PPS, Pinellia pedatisecta Schott; QRHX, Qing-Re-Huo-Xue formulae; RSV, resveratrol; SBS, Shen-ling-Bai-zhu San; SGJP, Shu-Gan-Jian-Pi formula; TADC, decoction tumor-associated dendritic cells; TAM, tumor-associated macrophage; TR, triptolide; YHD, Yang-He decoction; YPF, Yu-Ping-Feng.